Secondary AML

Know the seriousness of
their sAML diagnosis

sAML is a broad category of high-risk AML that includes multiple subtypes of leukemias with different characteristics. These subtypes have a similarly poor prognosis and significant challenge to reach a cure.^2,3

sAML includes multiple subtypes of high-risk AML^2,3

Patients with sAML face lower OS compared to those with de novo AML.⁴

3-year OS based on subtype⁴

Secondary AML

VYXEOS is a treatment
for t-AML and AML-MRC¹

t-AML is defined as AML arising after exposure to chemotherapy or radiotherapy for previous malignancies. AML-MRC is a multifaceted subtype that can be difficult to identify.^2,3

Click on the cards below to learn more about each subtype.

Know the seriousness of their sAML diagnosis

sAML includes multiple subtypes of high-risk AML2,3

3-year OS based on subtype4

VYXEOS is a treatment for t-AML and AML-MRC1

t-AML accounts for up to 10% of all AML cases and is defined as AML arising after exposure to chemotherapy or radiotherapy for previous malignancies.2,5

Prior malignancies associated with t-AML4

AML-MRC accounts for up to 35% of all AML cases6 and often occurs as de novo AML with MDS-related cytogenetic changes or multilineage dysplasia. Patients with AML-MRC may go unidentified without comprehensive testing.7

References

Definitions

Contact a Representative

Thank You

Know the seriousness of
their sAML diagnosis

sAML includes multiple subtypes of high-risk AML^2,3

3-year OS based on subtype⁴

VYXEOS is a treatment
for t-AML and AML-MRC¹

t-AML accounts for up to 10% of all AML cases and is defined as AML arising after exposure to chemotherapy or radiotherapy for previous malignancies.^2,5

Prior malignancies associated with t-AML⁴

AML-MRC accounts for up to 35% of all AML cases⁶ and often occurs as de novo AML with MDS-related cytogenetic changes or multilineage dysplasia. Patients with AML-MRC may go unidentified without comprehensive testing.⁷